Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

23.12
-0.3100-1.32%
Post-market: 23.120.00000.00%16:32 EDT
Volume:511.96K
Turnover:11.76M
Market Cap:1.53B
PE:-7.43
High:23.51
Open:23.35
Low:22.61
Close:23.43
52wk High:30.99
52wk Low:10.30
Shares:66.17M
Float Shares:36.76M
Volume Ratio:1.03
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1097
EPS(LYR):-2.5230
ROE:-41.01%
ROA:-26.14%
PB:3.26
PE(LYR):-9.16

Loading ...

Bicara Therapeutics to report first-quarter 2026 results, host conference call

Reuters
·
May 04

Bicara CMO David Raben disposes 5,500 shares worth $125,830

Reuters
·
Apr 29

Bicara Therapeutics announces annual shareholder meeting online

Reuters
·
Apr 27

Bicara CFO Ivan Hyep disposes 9,200 shares for $211,614

Reuters
·
Apr 23

Bicara Therapeutics CEO Claire Mazumdar disposes of common shares worth $354,145.5

Reuters
·
Apr 21

Bicara President, COO Ryan Cohlhepp disposes 12,500 shares for $287,591.25

Reuters
·
Apr 18

Bicara Therapeutics’ Earnings Call Highlights Pivotal Pivot

TIPRANKS
·
Apr 07

JonesTrading Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Apr 07

Bicara Therapeutics grants new employee stock option for 44,175 shares under inducement plan

Reuters
·
Apr 03

Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 03

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Bicara Therapeutics management to meet with Citizens

TIPRANKS
·
Apr 02

Stock Track | Bicara Therapeutics Soars 5.20% Intraday on Analyst Price Target Increases and Positive Forecasts

Stock Track
·
Apr 01

Wedbush Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Mar 31

Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday

Benzinga_recent_news
·
Mar 31

Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 31

Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Spyre Therapeutics (SYRE) and Henry Schein (HSIC)

TIPRANKS
·
Mar 31

Stock Track | Bicara Therapeutics Soars 5.68% Intraday on Phase 3 Trial Initiation and Financial Results

Stock Track
·
Mar 30

Bicara publishes corporate presentation on ficerafusp alfa in HPV-negative head and neck cancer

Reuters
·
Mar 30

BRIEF-Bicara Therapeutics Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Business Update

Reuters
·
Mar 30